Hydrogen Gas Shows Promise as Add-On Treatment for COPD
- Authors
- Shih-Feng Liu, Chin-Ling Li, Hui-Ching Lee, Hui-Chuan Chang, Jui-Fang Liu, Ho-Chang Kuo
- Journal
- Medicina
- Year
- 2024
- DOI
- 10.3390/medicina60020245
- Study Type
- Human
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- Taiwan
- Health Condition
- Chronic Obstructive Pulmonary Disease
- Body System
- Respiratory
TL;DR
Breathing in hydrogen gas may help improve the treatment of chronic lung disease.
Key Finding
The study investigated hydrogen gas as a complementary treatment for COPD based on its potential antioxidant and anti-inflammatory properties, though specific results were not available in the provided abstract.
Summary
This study examined whether hydrogen gas, used alongside standard treatments, could help people with COPD (chronic obstructive pulmonary disease—a lung condition that makes breathing difficult). Researchers hypothesized that hydrogen gas might work by reducing harmful inflammation and oxidative stress (cellular damage) in the lungs and body, potentially improving breathing and overall health in COPD patients.
Practical Takeaway
While this human trial suggests hydrogen gas warrants investigation as a COPD treatment, critical details about study results, participant numbers, and treatment duration are missing. Without access to the actual findings and methodology, it's impossible to assess whether hydrogen gas showed real benefits or how it compares to existing treatments. Anyone with COPD should discuss any new therapies with their doctor before trying them.
Abstract
Background and Objectives: Recent studies suggest that hydrogen gas possesses anti-inflammatory, antioxidant, and anti-apoptotic properties. This study aimed to explore the therapeutic potential of hydrogen gas and assess its safety and tolerability in individuals with chronic obstructive pulmonary disease (COPD). Materials and Methods: Enrolled COPD patients received standard treatments along with additional hydrogen inhalation for 30 min in the morning, afternoon, and evening over a 30-day period. The assessment included changes in the COPD Assessment Test (CAT), the modified Medical Research Council (mMRC) Dyspnea Scale, lung function, sleep quality, inflammation markers, and oxidative stress markers before and after hydrogen inhalation. Results: Six patients participated in this study. Patients 2, 3, 4, 5, and 6 demonstrated improvements in CAT scores following hydrogen gas intervention, with patients 2, 4, 5, and 6 also showing improvements in mMRC scores. Statistically, this study revealed significant improvements in CAT [15.5 (10.5–19.75) vs. 8.5 (3–13.5); p = 0.043] and mMRC scores [2.5 (1–4) vs. 2 (0–3.25); p = 0.046] before and after intervention, respectively. However, no significant differences were observed in lung function, DLCO, sleep quality, and 6 MWT before and after hydrogen therapy. CBC examination showed a significant difference in platelet count before and after treatment [247 (209.75–298.75) vs. 260 (232.75–314.5); p = 0.043], respectively, while other blood tests, inflammation markers, and oxidative stress markers did not exhibit significant differences before and after hydrogen therapy. All patients experienced no obvious side-effects. Conclusions: Adjuvant therapy with hydrogen gas demonstrated symptom improvements in specific COPD patients, and no significant adverse effects were observed in any of the patients. Hydrogen gas may also exert a modulatory effect on platelet count.